Purpose Vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) play a signiWcant role in glioblastoma angiogenesis and proliferation, making tyrosine kinase (TK) receptors logical targets for treatment. We evaluated AEE788, a reversible TK inhibitor that inhibits EGFR and VEGFR, in recurrent glioblastoma patients. Methods In this dose-escalation, phase I study, patients with recurrent glioblastoma received AEE788 once daily in 28-day cycles in stratiWed subgroups: those receiving (1) nonenzyme-inducing anticonvulsants drugs or no anticonvulsants (Group A) and (2) enzyme-inducing anticonvulsant drugs (Group B). A dose-expansion phase stratiWed patients by surgical eligibility. Primary objectives were to determine doselimiting toxicity (DLT) and maximum tolerated dose; secondary objectives included evaluating (1) safety/tolerability, (2) pharmacokinetics, and (3) preliminary antitumor activity. Results Sixty-four glioblastoma patients were enrolled. Two Group A patients experienced DLTs (proteinuria and stomatitis) at 550 mg; 550 mg was, therefore, the highest dose evaluated and dose limiting. One Group B patient receiving 800 mg experienced a DLT (diarrhea). The initially recommended dose for dose-expansion phase for Group A was 400 mg; additional patients received 250 mg to assess the hepatotoxicity. Most frequently reported adverse events (AEs) included diarrhea and rash. Serious AEs, most commonly grade 3/4 liver function test elevations, were responsible for treatment discontinuation in 17% of patients. AEE788 concentrations were reduced by EIACD. The best overall response was stable disease (17%). Conclusions Continuous, once-daily AEE788 was associated with unacceptable toxicity and minimal activity for the treatment of recurrent glioblastoma. The study was, therefore, discontinued prematurely.
Introduction
Glioblastoma, the most common primary malignant brain tumor in adults, is associated with a high degree of morbidity and mortality. The median survival time from diagnosis is approximately 1 year, even in patients who undergo aggressive treatment [1, 2] . For patients with recurrent glioblastoma, salvage therapies have been of limited value historically. However, recent studies have shown that therapies targeting vascular endothelial growth factor (VEGF), or its cognate receptor (VEGFR), can achieve durable antitumor beneWt in some patients with recurrent malignant glioma [3] [4] [5] [6] [7] [8] . Based on these Wndings, the Food and Drug Administration (FDA) recently granted bevacizumab, a humanized monoclonal antibody against VEGF, accelerated approval for patients with recurrent glioblastoma based on durable radiographic response [6, 7, 9] . Compared with historical benchmarks, however, only modest improvements in OS were noted in these studies. Nonetheless, rationally designed combinatorial strategies may further enhance the antitumor beneWt of VEGF/VEGFR-targeted therapeutics and show an improvement in OS [3] [4] [5] [6] [7] .
Results of several genomic studies have enhanced the characterization of the complex molecular composition of glioblastoma tumors [10] [11] [12] [13] . In particular, ErbB tyrosine kinase (TK) receptors, such as epidermal growth factor receptor (EGFR), have been shown to be signiWcantly upregulated in most glioblastoma tumors and play a signiWcant role in glioblastoma tumor survival, proliferation, and angiogenesis. Additionally, EGFR gene ampliWcation occurs in approximately 40% of glioblastoma tumors [14] [15] [16] [17] . Indeed, 50% of tumors with the ampliWed EGFR gene undergo intragene rearrangements responsible for an overexpression of mutant EGFR receptors (i.e., EGFRvIII), which demonstrate constitutive TK activity [18] [19] [20] . Based on these Wndings, several studies have evaluated the inhibition of EGFR activity as a treatment modality for glioblastoma. Studies evaluating EGFR-targeted therapies (e.g., erlotinib, geWtinib), however, have demonstrated minimal and/or mixed eYcacy results in glioblastoma patients, most likely because of various factors, such as the ability of glioma cells to develop compensatory mechanisms through other uninhibited pathways [20] [21] [22] . More eVective therapies may, therefore, be those that target several pathways. In preclinical glioblastoma models, combined targeting of the EGFR and VEGF pathways has demonstrated signiWcant antitumor activity [23] . AEE788, an orally active TK inhibitor (TKI), potently inhibits EGFR/ErbB-1 and HER-2/neu (ErbB-2) as well as the VEGF receptor KDR (VEGFR-2), making it a logical potential treatment for glioblastoma [24, 25] . This 2-arm, multicenter, dose-escalation, phase I study evaluated the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of AEE788 in adults with recurrent or relapsed glioblastoma. To determine the eVects of cytochrome P450 (CYP 450) enzyme inducers on the PKs of AEE788, patients were stratiWed into those receiving non-enzyme (cytochrome 3A4 [CYP3A4])-inducing anticonvulsants drugs (non-EIACDs) or no anticonvulsants drugs (ACDs) and those receiving enzyme (CYP3A4)-inducing anticonvulsants drugs (EIACDs; e.g., phenytoin, phenobarbitol, carbamazepine, oxcarbazepine, primidone).
Materials and methods

Study objectives
The primary objectives of the study were to assess doselimiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) of continuous, once-daily oral AEE788 as a single agent in patients with recurrent or relapsed glioblastoma who were receiving either non-EIACDs or no ACDs (dose-escalation Group A) or EIACDs (dose-escalation Group B). Secondary objectives included determining the safety, tolerability, and PK proWles of AEE788 and evaluating preliminary eYcacy of AEE788 in patients with recurrent glioblastoma.
Patient eligibility
The study enrolled adults (¸18 year of age) with histologically conWrmed glioblastoma who were experiencing a Wrst or second recurrence or relapse and had at least one measurable or evaluable enhancing lesion on baseline gadolinium-magnetic resonance imaging (Gd-MRI; standard brain magnetic resonance imaging that included precontrast and postcontrast images; postcontrast images obtained nondynamically using gadolinium chelate as contrast agent) performed within 3 weeks of study entry. Table 1 outlines additional eligibility criteria. Inclusion criteria: a Karnofsky performance status¸70; life expectancy¸12 weeks; an absolute neutrophil count¸1.5 £ 10 9 /L; hemoglobin leveļ 9 g/dL; platelet count¸100 £ 10 9 /L; serum bilirubin level ·1.5 £ upper limit of normal (ULN); serum creatinine level ·1.5 £ ULN (or 24-h creatinine clearancȩ 50 mL/min/1.73 m 2 ); and potassium, magnesium, calcium, and phosphorus all within normal limits. In the doseexpansion phase, patients treated with 250 mg were required to have normal liver function tests. Patients with a history of polifeprosan with carmustine intracranial wafer implantation were eligible at the discretion of the investigator and study sponsor.
Exclusion criteria included the presence of greater than grade 1 peripheral neuropathy or unresolved diarrhea, impaired cardiac function, or other signiWcant cardiovascular disease (e.g., uncontrolled hypertension, recent history of myocardial infarction), uncontrolled diabetes, an active or uncontrolled infection (including human immunodeWciency virus), a gastrointestinal condition or disease that could alter the absorption of AEE788, or another active malignancy. Patients were excluded if they had received any of the following: hematopoietic colony-stimulating factor or immunotherapy ·2 weeks before study entry; chemotherapy, investigational drugs, or radiation therapy ·4 weeks before study entry; and prior EGFR/ErbB-2-or VEGF/VEGFR-directed therapies. Patients receiving warfarin and digoxin for congestive heart failure or verapamil for cardiac arrhythmias were also excluded as were patients who had undergone surgery within 2 weeks of enrollment (1 week for stereotactic biopsy). Pregnant and breastfeeding women or adults with reproductive potential who did not employ eVective birth control were also deemed ineligible.
All study participants provided informed consent before study entry.
Study design
The dose was escalated according to a modiWed accelerated titration design for phase I studies described by Simon et al. [26] , which includes single-patient cohorts treated at each dose level until the second occurrence of a National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE; version 3.0) grade 2 toxicity or Wrst occurrence of a¸CTCAE grade 3 toxicity in cycle 1 where 3-6 patients will be enrolled in all subsequent cohorts. Although there was no¸CTCAE grade 2 toxicity up to 200 mg, the 100 mg cohort was expanded after 1 patient reported grade 4 transaminases elevation outside of the DLT observation period (28 days after the Wrst AEE788 dose). The MTD was deWned as the dose at which 0 or 1 out of 6 patients experienced DLT, with at least 2 patients experiencing DLT at the next higher dose. DLT was deWned (1) as an AE or abnormal laboratory value unrelated to disease progression, intercurrent illness, or concomitant medications that occurred during the Wrst 28 days after the Wrst dose of AEE788 during cycle 1, and (2) according to other predetermined criteria ( Table 2) . If no DLT occurred during a cycle, the patient continued treatment with AEE788 at the same dose as the previous cycle, unless the criteria for AEE788 dose interruption or modiWcation were met.
Based on the results of other phase I AEE788 studies, the starting dose of AEE788 for Group A patients was 50 mg [27, 28] . Because Group B patients were receiving anticonvulsants, which are expected to lower the exposure of AEE788 due to CYP 450-enzyme induction, enrollment for Group B began with the second occurrence of a CTCAE grade 2 or Wrst occurrence of a¸CTCAE grade 3 toxicity in Group A. The starting dose for Group B, however, was dependent on the aggregate toxicities observed in Group A and was one dose level below the dose that induced the AE.
Upon establishing an MTD in Groups A or B patients, 2 additional cohorts (arms 1 and 2) of glioblastoma patients were to be enrolled in the dose-expansion phase of the study to receive the MTD, so that safety, tolerability, biologic activity, systemic and intratumoral PK, and pharmacodynamic activity of AEE788 could be further evaluated (see Table 1 ). Arm 1 included patients experiencing a Wrst or second recurrence/relapse who were surgical candidates; patients experiencing their Wrst relapse/recurrence who were ineligible for surgery were included in Arm 2 ( Table 1) .
Pharmacokinetics
Single-and multiple-dose PKs (trough concentration, maximum concentration of drug [C max ], and area under the curve [AUC]) were assessed in all patients who received at least one dose of AEE788. Plasma PK data were evaluated at all dose levels. AEE788 tumor levels (intratumoral PK) were assessed in Group A, Arm 1 patients during dose expansion.
During cycle 1, PK blood sampling was performed before therapy administration on days 1, 8, 15, 22, and 28; multiple postadministration samples were obtained on days 1 and 15 (at 1, 2, 3, 4, 7, 10, 24 h) and day 28 (at 1, 3, 5, 9, 24 h). Preadministration samples were obtained on day 15 during cycle 2 and day 1 during cycle 3. A PK sample was collected within 2 h before surgery in the dose-expansion Arm 1, Group A patients who had been on AEE788 once daily for 5-9 consecutive days. Intratumoral PKs were determined using 60-to 70-mg tumor samples. A validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay with a lower limit of quantiWcation (LLOQ) of 0.5 ng/mL was used to assay serum samples for concentrations of AEE788 and its metabolite, AQM674. To determine intratumoral PK, tumor tissue samples were homogenized after they were mixed with phosphate-buVered saline. The homogenate was extracted for the analyte(s), and the extract was analyzed using LC-MS/MS. The LLOQ for tissue samples was 5 ng/g.
Intratumoral biomarker analyses
Unstained slides were prepared from formalin-Wxed, paraYn-embedded archived tumor blocks collected at initial glioblastoma diagnosis or recurrence. Each slide was stained for EGFR, p-4EBP1, p-AKT, p-KDR, p-MAPK, p-p70S6K, p-S6, or PTEN using the method described by Simmons et al. [31] . Slides were stained for EGFRvIII and p-EGFR only for EGFR-positive tumors. Samples were evaluated by immunohistochemistry (IHC). The IHC staining was scored on a scale from 0 to 200 according to the intensity of the stain and categorized by a 3-tiered system (tier 1: 0 = negative staining; tier 2: >0 and ·100 = light to light ¡ moderate staining; and tier 3: >100 = moderate-strong to strong staining). This exploratory analysis included at least 10 patients per group; Kaplan-Meier analyses were performed between tiers 1 and 2 versus tier 3 for p-4EBP1, p-AKT, p-KDR, p-MAPK, p-p70S6K, p-S6, and PTEN, and tier 1 versus tiers 2 and 3 for EGFR, p-EGFR, and EGFRvIII. Degree of staining was grouped as negative to light-moderate staining (tiers 1 and 2) versus moderate strong to strong (tier 3) for PTEN, p-AKT, p-S6, p-p70S6K, p-4EBP1, p-KDR, and p-MAPK, and negative (tier 1) versus light-strong (tiers 2 and 3) for EGFR, p-EGFR and EGFRvIII. 
EYcacy
Evaluations based on the Macdonald [32] criteria, including a neurologic examination and Gd-MRI to assess tumor response, were used to evaluate the eYcacy at baseline, the end of cycle 1, the end of each subsequently even-numbered cycle, and the end of study. Objective responses had to be conWrmed on consecutive Gd-MRI scans performed at least 1 month apart. Patients without measurable disease were not evaluable for radiographic response.
Changes in uptake of the positron emission tomography (PET) probe [ 18 F]-Xuoro-L-thymidine (FLT) was used to assess drug-induced changes in tumor cell proliferation at clinical centers where FLT was available. FLT scans were performed in dose-escalation and dose-expansion Arm 2 patients at baseline, on cycle 1 day 15 (optional), and on cycle 1 day 28. Cycle 1 day 28 parameters for all images were quantitated and compared to their respective baseline measurement. Dose-expansion Arm 1, Group A patients underwent FLT scans at baseline (·4 days before Wrst AEE788 dose) and day 1 (or within 48 h) before surgery. Dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) and dynamic susceptibility contrast (DSC)-MRI were performed to assess antiangiogenic eVects of the AEE788, and diVusion-weighted imaging (DWI)-MRI was performed to assess changes in tumor cellularity/necrosis in dose-expansion (Arm 2) patients.
Statistical analyses
All patients who received at least one dose of AEE788 were included in the intent-to-treat (ITT) population. The safety population included all patients who received at least one dose of AEE788 and underwent at least one postbaseline safety assessment. The MTD population included all patients from the safety population who either met the minimum exposure criteria (i.e.,¸75% planned cycle-1 doses) and underwent suYcient safety assessments (i.e., received AEE788 for¸21 days, was observed for¸28 days after the Wrst dose, and completed all safety evaluations) or discontinued the study before the end of cycle 1 due to DLT. Sample size estimates relied on the Shuster minimax 2-stage design for Arm 1 (based on 6-month progression-free survival [PFS] rate) and the multinomial 2-stage design for Arm 2, (based on response rates [RRs] and PFS rate at 8 weeks) because these patients had measurable disease and, using an early-stopping design, may be useful to allow for other treatment options in patients who are not responding [29, 30] . Patients were followed for disease progression (i.e., PFS) while on study only. Patients who did not have documented tumor progression before discontinuation had a censored PFS at the date of the last tumor assessment before study discontinuation. Descriptive statistics were used to summarize baseline patient characteristics and patient disposition. Safety data were summarized according to the type and frequency of AE. EYcacy data (i.e., RRs) were summarized according to the treatment schedule and group; Kaplan-Meier estimates were performed to determine the PFS and overall survival (OS) times. Summary statistics for the PK parameters AUC 0-24 , C max , time to maximum concentration (t max ), and accumulation index (RA) were calculated on days 1, 15, and 28 of cycle 1. PK parameters were determined using non-compartmental methods using WinNonlin Pro (version 3.2).
Three exploratory analyses were performed on the intratumoral biomarker data: (1) Spearman's rank correlation analyses were conducted to determine the correlation structure among p-KDR, p-S6, p-AKT, and PTEN and 6 other biomarkers (all as continuous variables); (2) univariate Kaplan-Meier analyses and log-rank tests were applied to each of the 10 biomarkers comparing IHC staining score ·100 vs >100 with respect to PFS; and (3) Cox proportional hazards models for PFS were applied to the 10 continuously measured biomarkers to get a parsimonious set of predictive biomarkers. Consistency of model selection was examined by using both stepwise and backward elimination variable selection methods. A 5% level of signiWcance was used as the cutoV for selection. No adjustments were made for the multiple comparisons.
Results
Patient characteristics
Between January 2004 and November 2005, 64 glioblastoma patients were enrolled in the study including 40 patients in the dose-escalation phase (26 patients, Group A; 14, Group B) and 24 in the dose-expansion phase (7, Arm 1; 17, Arm 2). The dose-escalation cohorts and the number of patients within each cohort are listed in Table 1. Table 3 presents baseline patient demographics and patient study disposition. All patients had PD after having undergone surgery and received radiation therapy and/or systemic chemotherapy before enrolling to the study.
Pharmacokinetics
Serum concentrations of both AEE788 and its primary metabolite AQM674 were highly variable. By day 15 of cycle 1, the mean coeYcient of variation in AUC 0-24 was 67% (range, 47-102%) for AEE788. AEE788 and AQM674 exposure increased with dose and dose duration (number of doses). In Group A, an 11-fold range in doses (50-550 mg) yielded a 52-fold range in exposure to the parent drug, suggesting the exposure of AEE788 exposure increases overproportionately with increased dose, while AQM674 exposure increased 20-fold (Table 4) . On average, the maximum serum concentrations of AEE788 and AQM674 occurred at 5 and 4.6 h after administration, respectively. The AQM674 serum concentration proWle appears to reXect relative changes in AEE788, suggesting rapid metabolite formation and elimination equal to or faster than those with AEE788. Parent and metabolite exposure was approximately 4.5-and 3-fold, respectively, greater on day 15 than day 1. Exposure of AEE788 and AQM674 after 15 and 28 days of dosing was similar, suggesting PK steady state was reached on or before day 15. Accumulation of both AEE788 and AQM674 was 2-8 times greater after daily (q 24 h) administration rather than a single dose, with a C max to minimum concentration (C min ) ratio (i.e., C max :C min ) of approximately 2. Because oral clearance is confounded by bioavailability, clearance is instead based on the exposure proWle of AEE788. Neither the nonlinear dose-exposure relationship of AEE788 nor the drug accumulation could be explained by a decrease in total systemic clearance, indicated by an increase in apparent terminal phase slope. The exposure patterns, however, were consistent with a Wrst-pass metabolism process by the gut and/or liver that can be saturated at high drug concentrations. The AEE788 dose-exposure relationship between Groups A and B exhibited nonlinear patterns for both AEE788 and AQM674 (Figs. 1 and 2 ). Overall exposure of parent and metabolite were reduced in patients receiving EIACD (Group B). For example, the exposure of Group B patients who received 600 mg was half the exposure observed in Group A patients who received 550 mg. This suggests that metabolism of AEE788 is susceptible to enzyme induction by EIACD. The eVective half-life, estimated from accumulation index with a 24-h dose interval, exceeds 24 h. Parent and metabolite reach pharmacologically active concentrations (i.e., concentration at which EGFR and VEGFR pathways are inhibited) in glioma tumor tissue (Table 5) . Four patients had their tumor surgically removed approximately 12 h after the eighth dose of AEE788 (250 mg). AEE788 and AQM674 tumor concentrations ranged from 2.9 to 7.1 and 0.21 to 0.92 M, respectively, while serum concentrations collected at the same time ranged from 0.10 to 0.32 and 0.05 to 0.07 M. The concentration of AEE788 in patient glioblastoma tumor samples was therefore 14-to 59-fold higher than in plasma. This is consistent with Wndings in an NCI-H596 lung carcinoma-bearing nude mice model (data on Wle). Consequently, AEE788 tumor concentrations achieved in this study exceeded concentrations required for tyrosine kinase-and cell growth-inhibition that has been observed in various in vitro models (data on Wle).
Intratumoral biomarker analyses
A total of 47 archival tumor samples obtained from enrolled patients were analyzed for all biomarkers. Of these 47 samples, 39 were collected at initial glioblastoma diagnosis and 8 at disease recurrence. Correlations between p-KDR, p-S6, p-AKT, and PTEN and other biomarkers are summarized in Table 6 . IHC staining greater than 100 (i.e., tier 3) for p-KDR and PTEN was found in 19 of 28 (68%) and 10 of 28 (36%) patients, respectively. Expression of p-EGFR was negative in 24 of 28 patients and correlated poorly with other markers. EGFRvIII mutation was present in 2 patients. PFS was inversely correlated with p-S6 (P = 0.04) and p-KDR (P = 0.03) expression according to log-rank analyses. However, the Cox proportional hazards analysis found that only Table 6 Correlations between p-KDR, p-S6, p-AKT, and PTEN and other biomarkers (5% level of signiWcance) (n = 47) *The lack of negative correlation of PTEN with p-AKT staining may be explained by the possibility that the functional status of PTEN is not reliably assessed via IHC staining. Alternatively, AKT pathway activation may occur by means independent of PISK and PTEN regulation, further reducing the likelihood that a correlation may be found p-KDR was a signiWcant predictor of PFS (inverse relationship, P = 0.01, both variable selection methods) [33] .
Dose-limiting and other toxicities
Initial dose-escalation cohorts for Group A included 50, 100, 200, 400, and 550 mg. DLTs occurred in 2 of 6 patients (grade 4 stomatitis [1 patient]; grade 2 proteinuria, grade 3 fatigue, and grade 3 atrial Wbrillation [1 patient each]) at 550 mg. Because no patients experienced a DLT at the 400-mg dose level, a cohort of 6 patients then received 450 mg. One of these 5 patients experienced a DLT (grade 2 seizure); however, because 1 of the initial 6 patients of this cohort withdrew consent and, therefore, was deemed ineligible for inclusion in the MTD-determining population, an MTD could not be deWned. Enrollment of Group B patients initiated when a grade 3 skin rash was reported in a Group A patient treated at 400 mg. The starting dose level of Group B was, therefore, 300 mg with subsequent cohorts receiving 600 and 800 mg. One of 6 patients experienced a DLT (grade 3 diarrhea resistant to antidiarrheal treatment) at 800 mg. The dose-expansion phase included 24 patients. Because 550 mg was dose limiting in 2 of 6 evaluable patients and 450 mg was dose limiting in 1 of 5 evaluable patients in Group A of the dose-escalation phase, 400 mg was the initially selected dose for the dose-expansion phase. Four patients with baseline AST or ALT levels of up to CTCAE grade 1 toxicity levels received 400 mg. An additional 18 patients with normal AST or ALT levels at baseline received 250 mg to further assess hepatotoxicity as initial safety data suggested less frequent liver function test abnormalities at dose levels of 250 mg or less. In Group B, 2 patients received 600 mg. Enrollment for the dose-expansion phase of the study was not completed because the sponsor terminated the study early after review of the PK, safety, and eYcacy data.
All patients reported at least one AE. Diarrhea was the most commonly reported, occurring in 72% of patients (grade 3, 9.4%; grade 4, none) and at similar rates in Groups A and B. Table 7 lists the most frequently occurring AEs by dose level. Twenty-eight percent (28%) of patients discontinued treatment because of AEs.
SAEs were more frequent in Group A than in Group B (42% vs 25%), causing 17% of patients to discontinue the study. Of the 64 patients enrolled in the study, 14 (22%) experienced grade 3/4 AST or ALT elevations, including 2 patients who had concurrent¸grade 2 total bilirubin elevation. Grade 2 and 3 AST or ALT abnormalities were observed in more Group B patients, while grade 3/4 AST or ALT elevations with concurrent¸grade 2 total bilirubin elevations and grade 4 AST or ALT elevations occurred in 2 Group A patients and 0 Group B patients. No relationship between higher AEE788 dose levels and AST or ALT abnormalities was observed. Three deaths (Group A: disease progression, 2 patients; and Group B: disease progression, 1 patient) occurred during AEE788 therapy, and 4 deaths occurred within 28 days of last dose of AEE788 (Group A: disease progression, 1 patient; pulmonary failure, 2 patients; and pneumonia, 1 patient).
EYcacy
No CR or PR was reported. The overall best response was SD for >3 cycles in 6 of 36 patients (17%); 4 Group A patients treated at doses 50-200 mg had SD for 6-10 months. Median PFS for patients treated in the doseexpansion phase was 2.7 (90% CI: 1.9, 2.8) and 1. FLT-PET was performed in 6 patients (3 at 250 mg; 1 at 400 mg; 2 at 600 mg). Ten patients (8 at 250 mg; 2 at 400 mg) underwent DWI-MRI, DCE-MRI, and/or MRI. Gd-MRI was performed on all patients. Overall, one patient experienced a signiWcant decrease in PET parameters, and no signiWcant pharmacodynamic eVects based on FLT-PET and/or MRI analyses were noted for patients at any dose level.
Discussion
The role of EGFR and VEGF in tumor cell development and progression and the potential beneWt of concomitantly targeting these cellular pathways to treat various tumor types are well described [24, [34] [35] [36] [37] [38] . Hence, we hypothesized that AEE788, a dual inhibitor of both EGFR-and VEGF-mediated pathways, would prove eVective for the treatment of glioblastoma, a tumor typically presenting with high VEGF concentrations, EGFR gene ampliWcation, and an overexpression of EGFR proteins. Our Wndings, however, demonstrate an unfavorable AE proWle and minimal activity of AEE788 in this population. The most frequently occurring AEs during all cycles (all dose levels) were diarrhea, rash, fatigue, nausea, hemiparesis, and ALT elevations. Grade 3-4 AST or ALT elevations occurred in 14 patients (22%). Although most cases occurred in patients receivinģ 250 mg, a relationship between AEE788 dose and AST or ALT abnormalities was not observed. DLTs were deWned as proteinuria, stomatitis, fatigue, and seizures. Whether the seizures experienced by 1 patient receiving AEE788 450 mg were truly an AEE788-related DLT versus an AE of the glioblastoma tumor itself is unknown; however, the investigator did suspect the event was related to AEE788. These safety and eYcacy Wndings are similar to those observed in other recently completed studies evaluating multitargeted TKIs (e.g., erlotinib, sorafenib, vandetanib, sunitinib), either alone or in combination with chemotherapeutic agents, for the treatment of glioblastoma as well as other tumor types (e.g., breast, kidney, thyroid) [39] [40] [41] [42] . As with the current study, many of these studies demonstrated "oV-target" or unexpected toxicities coupled with poor eYcacy outcomes. For example, in a recent phase I/II study evaluating erlotinib in combination with the mammalian target of rapamycin (mTOR) inhibitor temsirolimus in patients with recurrent glioblastoma or anaplastic gliomas (phase I, N = 22; phase II, N = 56), toxicities, particularly rash and mucositis, requiring signiWcant temsirolimus dose reductions were observed; furthermore, antitumor activity was minimal (glioblastoma patients: SD, 30% of patients; 6-month PFS, 12.5%; PR, none) [42] . Likewise, when temsirolimus was combined with sorafenib in patients with recurrent glioblastoma, several patients experienced grade 3, oV-target toxicities with the most common being thrombocytopenia (9 of 19 patients [47%]) and tumor RRs did not merit further study [41] . Although some oV-target toxicities, such as hypothyroidism and cardiotoxicity, which are often observed in patients receiving the multitargeted TKIs sorafenib or sunitinib for the treatment of renal cell and other carcinomas, are considered manageable with optimal patient monitoring and treatment, many oV-target toxicities are unmanageable and, thus, limit the use of many multitargeted therapies [43, 44] . For example, we observed dose-independent hepatotoxicity (i.e., at least grade 2 AST or ALT elevations) in 27% of Group A and 44% of Group B patients.
Collectively, the data from these and other studies highlight potential gaps in current methodologies evaluating multitargeted therapies. First, identifying the optimal biological dose (OBD) and/or minimally active dose (as opposed to the MTD) will be important to help deWne doseescalation methods. For targeted therapies, the OBD, however, takes into consideration the unconventional characteristics of targeted therapies, such as wider therapeutic indexes and diVering mechanisms causing therapeutic versus toxic eVects (i.e., mechanism-dependent vs mechanism-independent [i.e., oV-target] AEs), and may often be lower than the MTD for a given drug [45] . Determining the OBD requires that biologic markers (e.g., circulating VEGF levels, tumor vasculization, PK/pharmacodynamic relationships) predictive of optimal inhibition of the drug's target and, theoretically, tumor response be identiWed and validated in preclinical trials [45] . Additionally, proactively identifying subgroups of patients most likely to beneWt from a particular multitargeted therapy for inclusion in phase I/II clinical trial could optimize trial design and outcomes, while sparing patients unlikely to beneWt from a given therapy unnecessary drug exposure and associated toxicities [45] . Lastly, optimizing drug combinations is necessary to minimize additive toxicities and/or drug interactions that may require dose adjustments that can result in inadequate target drug exposure, particularly in glioblastoma patients who often require EIACDs [42] .
In conclusion, continuous, once-daily AEE788 was associated with minimal activity for the treatment of recurrent glioblastoma and unexpected, oV-target toxicities. After review of the PK, safety, and eYcacy data, the study was discontinued prematurely, and further study of AEE788 for the treatment of glioblastoma has been terminated.
